University of Hertfordshire

From the same journal

By the same authors

Guideline of Guidelines: Muscle Invasive Bladder Cancer

Research output: Contribution to journalArticlepeer-review

Documents

  • Guideline

    Final published version, 310 KB, PDF document

View graph of relations
Original languageEnglish
Number of pages8
JournalTurkish Journal of Urology
DOIs
Publication statusPublished - 21 Sep 2020

Abstract

Muscle-invasive bladder cancer accounts for 25% of bladder cancer cases and represents a spectrum of disease, which can result in significant morbidity and mortality for anyone affected. Current management has evolved through years of research and clinical practice. It is based on a risk-benefit approach, which is often tailored to the individual requirements of patients and involves cystectomy, neoadjuvant and adjuvant therapies, and multimodal surveillance paradigms to achieve high survival rates. Multiple guidelines exist to assist the clinicians in this decision-making process, but their adherence is often variable. In this article, we aimed to review the 4 most commonly used guidelines from the European Association of Urology, the National Institute for Health and Care Excellence, the National Comprehensive Cancer Network, and the American Urological Association.

Notes

© 2020 Turkish Society of Urology. Final publication available at https://dx.doi.org/10.5152/tud.2020.20337.

ID: 22541327